PredictImmune,a developer of pioneering prognostic products for guiding treatment options and improving patient outcomes in immune-mediated diseases,today announced the appointment of Paul Kinnon as its new Chief Executive Officer.He joins PredictImmune having spent over 20 years in anumber of successful executive positions in the United States.To date,PredictImmune has raised£4.7m Series Aequity funding for the commercial development of laboratory services and diagnostic kits for routine use in clinical gastroenterology,and an additional£4.3m investment from the Wellcome Trust to support aprospective multi-centre clinical trial of aprognostic biomarker product for treatment guidance in Crohn’s disease.Kinnon said:“This is an exciting time for PredictImmune and I’m honoured to have been appointed to lead the company as it enters the commercialisation phase of its expansion.I look forward to working with the highly qualified and experienced team at PredictImmune to implement the global commercialisation of its unique and revolutionary products to market and increase the company’s potential long-term value.”Immune-mediated diseases,such as inflammatory bowel disease,vasculitis and Lupus are common,chronic and incurable,and there is currently no way of knowing whether apatient is likely to experience asevere,relapsing form of the disease.PredictImmune’s innovative prognostic products will identify patients who may benefit from state-of-the-art(biologics)anti-inflammatory drugs.Andrew Sandham,Executive Chairman of PredictImmune,commented:“Paul has more than 25 years of global leadership experience in disruptive life science and diagnostics companies and has aproven track record in transforming organisations while driving commercial success and growth.I’m delighted to welcome Paul to the team and look forward to working with him to bring our ground-breaking products to market.”Kinnon began his career as an analytical chemist at Smithkline French&Beckman Research,a predecessor company of GlaxoSmithKline.Throughout his executive career,he has held leadership positions with Transgenomic,ZyGEM Corp.,Life Technologies,Guava Technologies and Cellomics,generating more than$60m in funding,creating global partnerships and increasing shareholder returns.Kinnon takes up his new position with immediate effect and will be based at PredictImmune’s UK headquarters at The Babraham Research Campus. 查看详细>>

Business Secretary Greg Clark today announced funding for aseries of ambitious technology projects that will transform the way medicines are discovered,enabling the pharmaceutical industry to develop groundbreaking drugs faster,cheaper and better than ever before.The projects are the first wave of major initiatives for the£103m Rosalind Franklin Institute,that launched today at the Harwell Campus,Oxfordshire.New drugs are discovered through aslow and painstaking process of trial and error,often taking ten years and billions of pounds to develop.The Rosalind Franklin Institute(RFI)is investing£6m to create:The World’s most advanced real-time video camera,the key to anew technique that uses light and sound to eradicate some of the most lethal forms of cancer.A new project pioneering fully-automated hands-free molecular discovery to produce new drugs up to ten times faster and transform the UK’s pharmaceutical industry.A ground-breaking new UK facility that will revolutionise the way samples are produced and harness Artificial Intelligence(AI)to generate new drugs for clinical testing within afew weeks.The RFI will harness disruptive new technologies such as AI and robotics to dramatically improve our understanding of biology,leading to new diagnostics,new drugs,and new treatments for millions of patients Worldwide.It will pioneer new ways of working with industry,as part of the UK’s AI and Data Grand Challenge,bridging the gap between university research and pharmaceutical companies or small businesses.This will build on the Government’s modern Industrial Strategy and put the UK at the forefront of the industries of the future. 查看详细>>